This induces a synthetic lethality in drug-resistant chronic myeloid leukemia in mice[11] and represents a beneficial therapeutic strategy in patients with AML.[12] Trametinib in combination with TKIs may prevent the development of drug resistance through its regulatory molecule MEK. This evidence concerns the gene MAP2K7 and acute myeloid leukemia.